

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC., APOTEX CORP., EMCURE PHARMACEUTICALS LTD.,
HERITAGE PHARMA LABS INC.,
HERITAGE PHARMACEUTICALS INC., GLENMARK
PHARMACEUTICALS INC., USA, GLENMARK HOLDING SA, GLENMARK
PHARMACEUTICALS LTD., MYLAN LABORATORIES LIMITED,
Petitioners,

v.

ELI LILLY AND COMPANY,
Patent Owner.

Case No: IPR2016-01429
Patent No. 7,772,209

JOINT NOTICE OF STIPULATION CONCERNING JOINDER

Three petitions for *inter partes* review have been filed seeking to join IPR2016-00318: IPR2016-01429 (filed by Apotex Inc., Apotex Corp., Emcure Pharmaceuticals Ltd., Heritage Pharma Labs Inc., Heritage Pharmaceuticals Inc., Glenmark Pharmaceuticals Inc., USA, Glenmark Holding SA, Glenmark Pharmaceuticals Ltd., and Mylan Laboratories Ltd.); IPR2016-01340 (filed by Teva Pharmaceuticals USA, Inc. and Fresenius Kabi USA, LLC); and IPR2016-01393 (filed by Wockhardt Bio AG). The Board held an initial telephonic conference in IPR2016-00318 on July 22, 2016, in which the petitioners in IPR2016-01429 and IPR2016-01340 participated. During that conference, the Board encouraged the parties to meet and confer regarding conditions for an agreed-upon joinder. The Petitioners in IPR2016-01429, IPR2016-01340, and IPR2016-01393 (collectively, the “Joinder Petitioners”), Petitioner Sandoz, Inc. (“Sandoz” or “Lead Petitioner”), and Patent Owner Eli Lilly and Company (“Lilly”) have conferred. Sandoz has indicated that it consents to joinder by the Joinder Petitioners and has no objection to Lilly and the Joinder Petitioners’ submission of this stipulation. Lilly and the Joinder Petitioners hereby stipulate and agree as follows:

1. Lilly will not oppose the joinder of Joinder Petitioners to IPR2016-00318 (the “Joined Proceeding”).

2. Lilly waives its right to file a Patent Owner Preliminary Response in IPR2016-01429, IPR2016-01340, and IPR2016-01393.

3. So long as Lead Petitioner is not terminated as a party, Lead Petitioner will retain control over petitioners' side of the Joined Proceeding, will conduct all argument and examination of witnesses for that side, and will submit all substantive written submissions for that side. Joinder Petitioners will act as silent understudies in the proceedings, and thus will not (1) file any papers or exhibits in the Joined Proceeding, except for *pro hac vice* motions, updated mandatory notices, and similar administrative filings that do not constitute argument or evidence relating to the merits; (2) serve objections or discovery requests in connection with the Joined Proceeding; however, these restrictions do not apply to any discovery requests Lilly may serve on a Joinder Petitioner; (3) participate in the questioning of any witness or the defense of any witness deposition in the Joined Proceeding; (4) participate in a speaking role in any telephonic conference before the Board in the Joined Proceeding; or (5) participate in oral argument in the Joined Proceeding. Joinder Petitioners may, however, attend all depositions, telephonic conferences, and oral argument in the Joined Proceeding, and will be served with all papers and exhibits served by Lead Petitioner on Patent Owner or by Patent Owner on Lead Petitioner. Notwithstanding the above, Joinder Petitioners may speak or otherwise respond if there is an argument, question, or

inquiry directed specifically to one or more Joinder Petitioners, or that is about one or more Joinder Petitioners specifically or the position of one or more Joinder Petitioners specifically.

4. The parties agree that the arguments and evidence presented in Joinder Petitioners' petitions is duplicative of the arguments and evidence presented in Lead Petitioner's petition. The Joined Petitioners agree to proceed in the instant IPR based only upon the arguments and evidence advanced by Lead Petitioner.

5. The presence of Joinder Petitioners in the Joined Proceeding shall not be a basis for any alteration of the schedule, nor shall Joinder Petitioners be allocated time or otherwise affect the times allocated for cross-examination, redirect, or re-cross examination of any witness.

6. In the event that Lead Petitioner is terminated from the Joined Proceeding by settlement or for any other reason, the remaining parties agree to confer in good faith regarding a fair and efficient framework for completing the remainder of the Joined Proceeding, including whether the submission of additional expert declarations from Joinder Petitioners (such as in the event that Lead Petitioner's expert is unavailable to the Joinder Petitioners) is necessary.

Date: August 22, 2016

/Dov P. Grossman/

Dov P. Grossman
Reg. No. 72,525
Lead Counsel for
Eli Lilly and Company

Williams & Connolly LLP
725 Twelfth Street, N.W.
Washington, D.C. 20005
202-434-5812 (Telephone)
202-434-5029 (Facsimile)
dgrossman@wc.com

/Deanne M. Mazzochi (with permission)/

Deanne M. Mazzochi
Reg. No. 50,158
Lead Counsel for
Apotex Inc. and Apotex Corp.

Rakoczy Molino Mazzochi Siwik LLP
6 West Hubbard St., Ste. 500
Chicago, IL 60654
312-527-2157 (Telephone)
312-527-4205 (Facsimile)
dmazzochi@rmmslegal.com

/Patrick A. Doody (with permission)/

Patrick A. Doody
Reg. No. 35,022
Lead Counsel for
Wockhardt Bio AG

Pillsbury Winthrop Shaw Pittman LLP
1650 Tysons Blvd.

/Gerard A. Haddad (with permission)/

Gerard A. Haddad
Reg. No. 41,811
Counsel for Glenmark
Pharmaceuticals Inc., USA, Glenmark
Holding SA, and Glenmark
Pharmaceuticals Ltd.

Blank Rome LLP
The Chrysler Building
405 Lexington Ave.
New York, NY 10174
212-885-5135 (Telephone)
917-591-6921 (Facsimile)
GHaddad@BlankRome.com

/Gary J. Speier (with permission)/

Gary J. Speier
Reg. No. 45,458
Lead Counsel for
Teva Pharmaceuticals USA, Inc.

Carlson, Caspers, Vandenburg,
Lindquist, & Schuman
225 South Sixth St., Ste. 4200
Minneapolis, MN 55402
612-436-9600 (Telephone)
612-436-9605
gspeier@carlsoncaspers.com

/Paul M. Zagar (with permission)/

Paul M. Zagar
Reg. No. 52,392
Counsel for Emcure Pharmaceuticals
Ltd., Heritage Pharma Labs Inc., and
Heritage Pharmaceuticals Inc.

Blank Rome LLP
The Chrysler Building

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.